Stocks and Investing
Stocks and Investing
Wed, March 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Judah Frommer Maintained (ATAI) at Buy with Decreased Target to $9 on, Mar 7th, 2023
Judah Frommer of Credit Suisse, Maintained "Atai Life Sciences N.V." (ATAI) at Buy with Decreased Target from $11 to $9 on, Mar 7th, 2023.
Judah has made no other calls on ATAI in the last 4 months.
There are 2 other peers that have a rating on ATAI. Out of the 2 peers that are also analyzing ATAI, 0 agree with Judah's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Judah
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Thursday, January 19th, 2023
- Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Decreased Target to $10 on, Monday, January 9th, 2023
Contributing Sources